Benjamin P. Saylor

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

The investigators reported that there were 24 evaluable patients with CIS with/without papillary disease, of whom 79% had a CR at 3 months.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.

The median number of re-injections was 6 (range, 1-12).

"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.

In both racial cohorts, median MFS was not reached in the darolutamide group.

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

The investigators reported an HR for OS of 0.796 (95% CI, 0.661-0.958; 2-sided P = .0155) for talazoparib/enzalutamide vs enzalutamide/placebo.

The treatment combination was associated with median radiographic progression-free survival of 14.3 months vs 6.2 months with enzalutamide alone.

The NDA is supported by data from cohort 2 of the phase 2b SunRISe-1 trial.

Results from CREST will be presented at an upcoming medical conference.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

As the year comes to a close, we revisit some of this year’s top video content from Urology Times.

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging agents in urology.

"Overall, the take-home message is that in patients with BCG-unresponsive non–muscle invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients," said Vikram Narayan, MD.

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.

CR rate was 98% (39/40) at 3 months, 94% at 6 months (34/36), and 81% at 12 months (21/26).

The priority review decision is based on results of the phase 3 NIAGARA study (NCT03732677).

As centrally assessed, the CR rate was 83.5% (95% CI, 73.9-90.7); the CR rate was 85.9% (95% CI, 76.6-92.5) per investigator assessment.

At month 6, the overall high-grade complete response rate was 72% (13 of 18

The overall complete response rate was 74.5% (95% CI, 65.4%-82.4%).

Anemia was the most frequently observed any-cause AE and was seen in 485 (84.2%) patients.

Overall median time from first documented biomarker test date to index date was 5.5 months.

“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.

"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.

68.8% of patients had at least a 30% improvement in ventral curvature from baseline.

“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.